Clinical Trial Finder

Inclusion Criteria.

• - Subject is able to provide written, informed consent and comply with the study protocol.

• - Subject is at least 18 years of age.

• - Subject has a diagnosis of plaque-type palmar and/or plantar psoriasis.

• - Patient has at least one psoriatic plaque outside of the palms and soles or psoriatic nail findings.

• - Subject has a ppPGA ≥ 3 at screening/baseline visit.

• - Subject is using adequate birth control during the study period as defined as follows: 1.

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR. 2. Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide. OR. 3. Option 3: Abstinence from sex when it is a lifestyle choice, and not just a social circumstance. Exclusion Criteria.

• - Subject is not able to provide written, informed consent and comply with the study protocol.

• - Subject is less than 18 years of age.

• - Subject has non-plaque type psoriasis on the hands and/or feet.

• - Patient does not have any evidence of psoriasis elsewhere.

• - Subject has concurrent cutaneous disease affecting the hands and/or feet that would interfere with assessments.

• - Subject has a ppPGA < 3 at screening/baseline visit.

• - Subject refuses to discontinue concomitant prescription medications on hands and/or feet.

• - Subject has used topical prescription treatments or received phototherapy treatment for psoriasis within 2 weeks of screening/baseline visit.

• - Subject has used intralesional kenalog within 4 weeks of screening/baseline visit.

• - Subject has taken oral treatments for psoriasis within 4 weeks of screening/baseline visit.

• - Subject has received any treatment with biologic medications within 5 half-lives (if known) or 16 weeks prior to screening/baseline, whichever is longer.

• - Subject refuses to use adequate birth control during the duration of the study period.

• - Subject is currently pregnant or breastfeeding.

Plaque type psoriasis of the hands and/or feet affects approximately 3-4% of patients with psoriasis. It is characterized by well-defined erythematous desquamative plaques located on the palms and soles, which may be limited to acral involvement or occur in combination with generalized psoriasis. Psoriasis that affects the hands and/or feet has a profound impact on quality of life (QoL) as it contributes to more physical disability and discomfort than patients with other forms of psoriasis, such as difficulty walking or using the hands. Furthermore, psoriasis of the hands and/or feet is generally considered a therapeutic challenge because the thicker stratum corneum reduces the penetration of topical treatment agents. Systemic treatments (retinoids, psoralen-ultraviolet A [PUVA], methotrexate, cyclosporine, and biologic therapy) have shown limited efficacy on psoriasis in acral areas. Unfortunately, patients with hand and/or foot involvement often have too low of body surface area (BSA) to participate in clinical trials for new psoriasis treatments, resulting in limited studies among this sub-population and no clear treatment algorithm. The high unmet need for an effective treatment for psoriasis of the hands and/or feet has been addressed in recent years with the development of new medications for generalized psoriasis that may also be effective in treating disease localized to acral areas. In 2015, two multicenter, double-blind, randomized, parallel-group phase 3 studies were conducted to assess the safety, tolerability, and efficacy of lotion containing a combination of halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ). The study population was subjects with moderate-to-severe psoriasis. The study results found that treatment success (defined as at least a 2-grade improvement from baseline Investigator Global Assessment score and a score of clear or almost clear) was achieved in around 40% of subjects by week 8, with substantial reductions in affected BSA, improvement in QoL, and a significant reduction in signs and symptoms of psoriasis. These phase 3 studies did not include a sub-analysis of the effect of HP/TAZ on psoriasis of the hands and/or feet. Given that topical steroids and topical retinoids are separately recommended as treatment options for psoriasis of the hands and/or feet, an agent that safely combines these medications

• - and that has demonstrated safety and efficacy in generalized psoriasis - offers a potential treatment for psoriasis of the hands and/or feet.

The purpose of the study described in this protocol is to evaluate the effect of HP/TAZ on plaque type psoriasis of the hands and/or feet after 24 weeks of daily treatment. In addition, given the impact of this variant of psoriasis on QoL and the relative lack of currently available treatment options, this study will also evaluate the impact of HP/TAZ treatment on patient-reported QoL measures and treatment satisfaction scoring.

Arms

Experimental: Participants with plaque type psoriasis

Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion) to be applied thinly once a day on the affected areas of hands and/or feet.

Interventions

Drug: - Duobrii®

Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.